Premium
Preliminary clinical experience with cis ‐diamminedichloroplatinum (II) (NSC 119875, CACP)
Author(s) -
Rossof Arthur H.,
Slayton Robert E.,
Perlia Charles P.
Publication year - 1972
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197212)30:6<1451::aid-cncr2820300606>3.0.co;2-q
Subject(s) - medicine , toxicity , vomiting , leukopenia , nausea , gastroenterology , anemia , dose , bone marrow suppression
Thirty‐one patients with metastatic cancer were treated with cis ‐diamminedichloroplatinum (II), CACP, in dosages ranging from 7.5 to 200 mg/m 2 BSA per course. Twenty‐two patients received more than one course. Toxicity to the initial course of CACP, up to 90 mg/m 2 BSA, was minimal and transient in most patients. At higher dosage levels or following repeat courses, the drug‐related toxicity was more severe. Drug‐related toxicity was more severe in patients with abnormal excretory tracts. The most common and earliest side effects were nausea and vomiting. Hyperuricemia commonly occurred shortly after administration of CACP. A dosage‐dependent, generally transient, nephrotoxicity was noted within the first 10 days after a course of CACP. Moderate leukopenia and thrombocytopenia, as well as a progressive normocytic anemia with marrow erythroid hypoplasia, were observed as late as 3 to 4 weeks after injection of this agent. Audiologic impairment above the frequency range of normal speech was detected by audiometry. Objective tumor regression was seen in five patients, four of whom experienced moderate‐to‐severe toxicity.